Our Leadership

Sheng Yao, Ph.D., Chief Executive Officer and Executive Director

Co-founder of Shanghai Junshi Pharma and TopAlliance Biosciences
Research fellow in immunology at the Mayo Clinic College of Medicine and Johns Hopkins University
Trained under the guidance of immunotherapy pioneer, Dr. Lieping Chen
B.S. Biotechnology from Peking University and Ph.D. from Albert Einstein College of Medicine

Co-founder of Shanghai Junshi Pharma and TopAlliance Biosciences
Post-Doctoral Researcher at Albert Einstein College of Medicine.
B.S. Degree from Tsinghua University and Ph.D. in Molecular Pharmacology from Albert Einstein College of Medicine

Former Acting Associate Director of Medical Policy Oncology Center for Excellence (OCE), Office of the commissioner
Division Director of Oncology Products (16 years)
Deputy Director Division of Clinical Trial Design and Analysis (4 years)
Chief and Medical officer at Oncology Branch (8 years)
Clinical Assistance Professor and medical oncologist at University of North Carolina at Chapel Hill
B.S. in Biology from University of Illinois Champaign-Urbana and M.D. from Loyola University Stritch School of Medicine
Completed her residency in internal medicine at the Loyola University Medical Center, Maywood, Illinois, and her fellowship in medical oncology at Roswell Park Memorial Institute, Buffalo, New York

Joined TopAlliance since 2020
Oversee the all regulatory-related activities
Former Director of Regulatory Affairs at AstraZeneca BioVentures and Head of Regulatory Affairs at Centus Biotherapeutics
Former Product Quality Reviewer at the Office of Biotechnology Products (OBP) and the Office of Life Cycle Product at CDER/FDA
B.S. in Biotechnology from Peking University and Ph.D. from University of Illinois at Urbana-Champaign

Responsible for developing and executing the clinical portfolio/project management strategies on behalf of the CMO
Industry Executive Leadership roles in Regulatory Affairs and Project Management (3 years)
Chief, Project Management Staff for the Division of Oncology Products 2 in the Office of Oncologic Diseases, CDER, US FDA (8 years)
Regulatory Project Manager/Team Leader for the Division of Oncology Products 2 in the Office of Oncologic Diseases, CDER, US FDA (10 years)
B.S. in Combined Science Biology/Chemistry and M.S. in Molecular Biology from Youngstown State University

Responsible for the translational and development functions.
Oversee new target validation and antibody discovery through pre-clinical development.
Participated in the development of multiple programs that advanced to clinical and pre-clinical stages
B.S. from the University of Science and Technology of China and Ph.D. degree from the University of Texas Southwestern Medical Center at Dallas

Former Executive Director and Principal Clinical Consultant at DataRevive.
Former Team Leader at the Office of Hematology and Oncology Products in the Center for Drug Evaluation and Research (CDER) at FDA.
Former Team Leader in the Office of Cell, Tissue, and Gene Therapy in the Center for Biologics Evaluation and Research (CBER) at FDA.
During her tenure at the FDA, Dr. Maher served as the chief clinical reviewer for several blockbuster cancer drugs, such as bevacizumab, pazopanib, crizotinib, avelumab, atezolizumab, and durvalumab.
Former Medical Oncologist at Schering-Plough Institute, the National Cancer Institute and the Tulane Medical Center.
Received Doctorate of Medicine from the Temple University School of Medicine, completed medical residency at the Washington Hospital Center and Hematology/Medical Oncology fellowship at the University of Massachusetts Medical Center.

Chairman of Nomination Committee & Member of Audit Committee and Remuneration Committee

Chairman of Audit Committee and Remuneration Committee & Member of Strategic Committee